R-Pharm

R-Pharm is an international pharmaceutical company headquartered in Russia.[1][2][3][4][5] It reached the headlines in 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection.[6] It was founded by Alexey Repik (ru) in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.[7]

Activity

The company's scope of activities covers areas related to the development, research, production, marketing of drugs intended primarily for inpatient and specialized medical care.[8] The main areas of activity are: production of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotechnological substances, research and development of drugs and technologies, introduction to the Russian market of pharmaceuticals.[9]

COVID-19

In 2020, during the COVID-19 outbreak in Russia, the company announced its intention to assist in the mass production of the Sputnik V COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It also announced that it had received a license to manufacture the British Oxford–AstraZeneca COVID-19 vaccine.[10] The company also manufactured the drug Coronavir, which has been described as the first prescription drug specifically developed against COVID-19 to reach the market. It was approved for use in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use.[6]

In December 2020, R-Pharm and the Gamaleya Research Institute of Epidemiology and Microbiology signed a Memorandum of Understanding with AstraZeneca to collaborate on the development of the COVID-19 vaccine and to conduct joint trials of the British and Russian vaccines.[11]

See also

References
  1. About company История Компании (History of R-Pharm).
  2. R-Pharm. www.weforum.org, accessed 23 June 2021.
  3. R-Pharm ZAO. www.bloomberg.com, accessed 23 June 2021.
  4. О КОМПАНИИ ГК «Р-Фарм» – российская высокотехнологичная фармацевтическая компания полного производственного цикла (tr. "ABOUT: R-Pharm Group of Companies is a Russian high-tech pharmaceutical company with a full production cycle "). archive.wikiwix.com, accessed 23 June 2021.
  5. Рейтинг крупнейших компаний России по объему реализации продукции* (archived copy) (tr. "Rating of the largest Russian companies in terms of product sales *"). archive.wikiwix.com, accessed 23 June 2021.
  6. Reuters Staff (2020-09-18). "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters (in French). Retrieved 2020-09-20. {{cite news}}: |author= has generic name (help)
  7. HERBERT SMITH FREEHILLS ADVISES MITSUI ON STRATEGIC ACQUISITION OF A 10% INTEREST IN RUSSIA'S R-PHARM 28 April 2017 www.herbertsmithfreehills.com, accessed 9 May 2023
  8. "Японская Meiji выходит на российский фармацевтический рынок" [Japanese Meiji enters the Russian pharmaceutical market]. 24 March 2012. Retrieved 18 February 2021.
  9. "В Томске открылся научно-образовательный центр подготовки специалистов для фармотрасли" [A scientific and educational center for training specialists for the pharmaceutical industry opened in Tomsk]. 8 November 2012. Retrieved 18 February 2021.
  10. ""Р-Фарм" договорилась с британской АstraZeneca о производстве вакцины от коронавируса" [R-Pharm has agreed with the British AstraZeneca to produce a vaccine against coronavirus]. 17 July 2020. Retrieved 2021-02-18.
  11. "Путин поздравил Центр Гамалеи, AstraZeneca, РФПИ и "Р-Фарм" с подписанием меморандума" [Putin congratulated the Gamaleya Center, AstraZeneca, RDIF and R-Pharm on signing the memorandum]. 21 December 2020. Retrieved 2021-02-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.